Relevance of sympathetic overactivity in hypertension and heart failure Therapeutic Implications
|
|
- Bruno Joshua Ramsey
- 6 years ago
- Views:
Transcription
1 Relevance of sympathetic overactivity in hypertension and heart failure Therapeutic Implications Uta C. Hoppe, MD, FESC Dep. of Internal Medicine II Paracelsus University Salzburg Austria
2 Disclosures Within the past 12 months, I have had a financial interest/arrangement or affiliation with the organization(s) listed below. Affiliation/Financial Relationship Company 1. Honoraria for lectures Astra, Bayer, Berlin Chemie, CVRx, Medtronic, Sanofi Aventis, Servier 2. Honoraria for advisory board activities Medtronic, Servier 3. Participation in clinical trials Ardian, Bosten Scientific, Boston, Braun, Cardiac Dimension, CVRx, Medtronic, Novartis, Remon, Sanofi- Aventis, Servier, Vessix Vascular 4. Research funding DFG, BMBF, ZMMK, Köln Fortune, Cardiac Dimension
3 Medical therapy in systolic heart failure Key role of sympathetic and neurohumoral blockade possibly Digitalis Aldosterone antagonist Diuretics Beta-Blockers ACE inhibitors or Angiotensine receptor blockers NYHA I NYHA II NYHA III NYHA IV ESC guidelines 212
4 Pentagram of antihypertensive drug combinations Diuretics Betablocker * Calcium channel blocker AT 1 -Antagonist ACE-Inhibitor Combination synergistic Combination possible * Combination for Dihydropyridine only Leitlinien zur Diagnostik und Behandlung der arteriellen Hypertonie 29; Dt. Hochdruckliga e.v. DHL - Deutsche Hypertonie Gesellschaft
5 Therapy-refractory arterial Hypertension - No achievement of target BP values - Exclusion of secundary hypertension - Adequate live stile modification - 3 antihypertensive drugs (including diuretics) - Approximately 8% of all hypertensive patients
6 Renal Denervation by catheter ablation
7 Reduction of systemic sympathetic Activity MSNA of patient with resistant Hypertension Baseline 1 M FU 12 M FU ECG 2 BP /17 mmhg 141/9 mmhg 127/81 mmhg MSNA 1 sec 56 bursts/min 41 bursts/min 19 bursts/min Improvement in cardiac baroreflex sensitivity after renal denervation (from 7.8 to 11.7msec/mmHg). Schlaich et al. NEJM 29;361:932
8 NA Spillover (ng/min) Effect of renal Denervation on renal and total Noradrenalin spillover NA Spillover (ng/min) Total renal NA spillover Total body NA spillover Mean office BP 161/17 141/9 Baseline - 47% p=.23 3 d post bilat. Denervation Left kidney Right kidney Baseline -28% p=.43 3 d post bilat. Denervation Schlaich et al. NEJM 29;361:932
9 Change of office BP after 6 months (mmhg) Renal Denervation by catheter ablation n=16; SBP 16 mmhg, 3 antihypertensive drugs, egfr of 45 ml/min/1.73m 2 Change of Office Blood Pressure after 6 months P< Systolic BP Renal Denervation Control Diastolic PB Esler et al. Lancet 21;376:193
10 Renal Denervation: Office Blood Pressure Change Maintained Blood Pressure Reduction over Time BP change (mmhg) Krum et al., ACC 212; Krum et al., Lancet 29;373;1275
11 Change from baseline to 3 months (mmhg) Cardiorespiratory Response to Exercise after RD Change of Blood Pressure at rest, maximum work rate and recovery RD (n=37) Control (n=9) SBP at rest DBP at rest SBP at peak work DBP at peak work SBP at recovery DBP at recovery Increase in max. work rate by 5 ± 13 W after RD Ukena et al. JACC 211;58:
12 Cardiorespiratory Response to Exercise after RD % of maximum work rate Ukena et al. JACC 211;58:
13 Change from baseline to 3 months (bpm) Change of heart rate (bpm) Cardiorespiratory Response to Exercise after RD Change of Heart rate at rest, maximum work rate and recovery Chronotropic reserve after RD Baseline 3 months after RD RD (n=37) Control (n=9) HR at rest Peak HR HR recovery 91% of pts. on beta-blockers % of maximum work rate Ukena et al. JACC 211;58:
14 Sympathetic Overactivity in arterial Hypertension and Heart Failure Baroreflex Hypertrophy Heart Failure Vasoconstriction Renin Na + /Volumen GFR
15 Baroreflex Activation Baroreflex- Stimul.-Sonden Implantierbarer Pulsgenerator
16 DEBuT 4-year Blood Pressure Reduction
17 Baseline BP or HR (mmhg or bpm) Change in BP or HR (mmhg or bpm) Barostim neo Trial Baseline BP or HR 3-month change of BP or HR by Baroreflex Activation SBP DBP HR SBP DBP HR History of RD (n=6) No History of RD (n=24) Hoppe et al. J Am Soc Hypertens. 212;6:27-6
18 Cardiovasc. Events (per 1 pts. years) Total Mortality (per 1 pts. years) Left ventricular mass - Prognosis Cardiovascular Events Total Mortality LV Mass-Index (Quintile) LV Mass-Index (Quintile) n=1925 Follow-up 4 years Schillaci et al, Hypertension 2
19 Effect of BP Reduction on LV Hypertrophy Dependence on treatment [%] -2-4 Meta-Analysis AT1 Receptor- Antagonist CA-Antagonist ACE-Inhibitor Diuretic Beta-Blocker Klingbeil et al. Am J Med 23; 115: 41-46
20 LVMI (g/m 2.7 ) IVSTd (mm) Regression of LV Hypertrophy after RD Resistant Hypertension; on average 4.7 antihypert. drugs: 46 pts. bilateral RD vs.18 pts. control LV mass index Interventricular septum thickness 8 7 p=.1 p<.1 p=.64 p=.81 p= p=.5 p= p=.855 p=.337 p= % Baseline 1 Month 6 Months RD Baseline 1 Month 6 Months Control Brandt et al. JACC 212;59:91-99
21 LVMI-Reduction (Δg/m 2.7 ) Regression of LV Hypertrophy after RD Resistant Hypertension; on average 4.7 antihypert. drugs: 46 pts. bilateral RD vs.18 pts. control Reduction of LV mass index 5 1 Month 6 Months -5-1 LVH no LVH -15 p=.8-2 p=.9 Brandt et al. JACC 212;59:91-99
22 LV Mass Index (g/m 2 ) Regression of LVH by Baroreflex Activation Reduction of LV Mass Index p-value < N = 6 Baseline N = 6 12 Months Bisognano et al. JACC 2112;57:1787
23 Mortality % Diastolic Dysfunction - Prognosis 25 - Total Mortality P<.1 moderate/severe diast. dysfunction mild dysfunction 5 - normal Years Schillaci et al, Hypertension 2
24 Mitral valve lateral E/E' Mitral valve lateral E/E' reduction Renal Denervation improves Diastolic Dysfunction Resistant Hypertension; on average 4.7 antihypert. drugs: 46 pts. bilateral RD vs.18 pts. control Intracardiac diastolic pressure 16 p<.1 p= Month 6 Months 14 p=.329 p<.1 p< Baseline 1 Month 6 Months -6 p<.1 p=.13 RD Control Baseline lat. E/É < Median Baseline lat. E/É > Median Brandt et al. JACC 212;59:91-99
25 Mitral valve lateral E/E' Renal Denervation improves Cardiac Function Resistant Hypertension; on average 4.7 antihypert. drugs: 46 pts. bilateral RD vs.18 pts. control Intracardiac diastolic pressure Systolic function p<.1 p=.6 p=.329 p<.1 p<.1 LVEDV 32.8±15.6 ml 25.6± months after RD; p= Baseline 1 Month 6 Months RD Control LV-EF 63.1±8.1 % 7.1± months after RD; p=.1 Brandt et al. JACC 212;59:91-99
26 Regression of LV Hypertrophy and Improvement of Cardiac Function after RD Potential Mechanisms - Blood pressure reduction per se - Direct sympatholytic effects on cardiomyocytes and fibrosis - Indirect effects on cardiomyocytes and cardiac matrix via metabolic modulation
27 Percentage of individuals Prevalence of Insulin Resistance in Hypertension Insulin sensitive intermediate resistant 39% 34% 47% 52% Untreated hypertension (n=56) Treated hypertension (n=7) 14% 14% < >18 Steady-state plasma glucose (SSPG, mg/dl) during the insulin suppression test Lima et al. Am J Hypertens 29;22:16
28 Change in fasting glucose (mg/dl) Change in fasting C-peptide (ng/ml) Change in fasting glucose (mg/dl) Change in fasting C-peptide (ng/ml) Effect of renal Denervation on Glucose Metabolism Change in fasting insulin (µiu/ml) Change in HOMA-IR (ng/ml) Change in fasting insulin (µiu/ml) Change in HOMA-IR (ng/ml) A A Change in fasting glucose (mg/dl) A A Change in fasting glucose (mg/dl) 1 month 1 month 3 months 3 months month 1 month 3 months 3 months Fasting glucose B 17.5 p=.589 p= p= p=.589 p=.177 p= p=.177 p= Renal denervation Renal denervation (n=35) (n=35) -1 p=.7 Renal Control denervation (n=15) (n=35) p=.7 Renal Control denervation (n=15) (n=35) -1 p= p=.7 p=.4 p=.4 Control (n=15) Control (n=15) -15 p= p=.4-15 B Change in fasting insulin (µiu/ml) B B Change in fasting insulin (µiu/ml) 1 month 1 month 3 months 3 months 1 monthp= monthp= months 3 months 15 p=.343 p= p=.927 p= p= p= p=.42 p= Insulin Renal denervation Renal denervation (n=35) (n=35) Renal Control denervation (n=15) (n=35) p=.42 Renal Control denervation (n=15) (n=35) p=.3 p=.3 p=.42 Control (n=15) Control (n=15) p=.3 p=.3 C C Change in fasting C-peptide (ng/ml) C C Change in fasting C-peptide (ng/ml) 1 month 1 month 3 months 3 months 1 monthp= monthp= months 3 months D 2. p=.356 C-Peptide p=.356 D p=.815 p= p= p= Renal denervation (n=35) Renal denervation (n=35) -2.5 Renal Control denervation (n=15) Renal denervation (n=35) (n=35) -2 Control (n=15) Control (n=15) Control (n=15) p= p=.22 p=.5 p= p=.22 p=.22 p=.5 p= Change in HOMA-IR (ng/ml) D D Change in HOMA-IR (ng/ml) Insulin sensitivity index 1 month 1 month 3 months 3 months 5 1 month 1 month 3 months 3 months 5 p=.246 p= p=.246 p= p=.962 p= p= p= Renal denervation Renal denervation (n=35) (n=35) Renal Control denervation (n=15) (n=35) -3 Renal Control denervation (n=15) (n=35) -4 Control (n=15) p=.23-4 p=.1 Control (n=15) p=.23 p=.1 p=.23-5 p=.23 p=.1 p=.1-5 Mahfoud et al. Circulation 211;123:194
29 Patients (%) Effect of RD on Glucose Metabolism Renal denervation (n=37) Control group (n=13) % 54% 32% n=3 n=4 6% 51% 43% 23% 46% 31% n=2 n=1 38% 38% 24% Diabetes IGT, IFG, or both NGT Baseline 3 months Baseline 3 months Mahfoud et al. Circulation 211;123:194
30 Total mortality % ASCOT-BPLA - study pts., atenolol±thiazide-based vs. amlodipine±perindopril-based therapy p =.247 Total Mortality Atenolol Thiazide (82 Events) Amlodipine Perindopril (738 Events) Years Terminated prematurely Dahlöf et al., Lancet 25; 366:
31 Effect of Central Hemodynamics on Outcome Risk for 1 mmhg increase of central Pulse Pressure and cardiov. Events Risk for 1% increase of central Alx and total Mortality Vlachopoulos et al., Eur Heart J 21;31:1865
32 Pressure (mmhg) Pressure (mmhg) Conduit Artery Function Evaluation (CAFE) study 2199 pts., atenolol±thiazide-based vs. amlodipine±perindopril-based therapy Peripheral pulse waveforms Central aortic waveforms Time (sec) Time (sec) equivalent brachial blood pressure reduction Williams et al. Circulation 26;113:1213
33 Conduit Artery Function Evaluation (CAFE) study 2199 pts., atenolol±thiazide-based vs. amlodipine±perindopril-based therapy Effect of therapy on Systolic BP: peripheral vs. central Williams et al. Circulation 26;113:1213
34 Conduit Artery Function Evaluation (CAFE) study 2199 pts., atenolol±thiazide-based vs. amlodipine±perindopril-based therapy Effect of therapy on Pulse Pressure: peripheral vs. central Williams et al. Circulation 26;113:1213
35 Peripheral BP (mmhg) Central aortic BP (mmhg) Effect of RD on peripheral & central aortic waveforms Peripheral pulse waveforms Central aortic waveforms Baseline 1 Month AP Baseline 1 Month AP Time (ms) Time (ms) Applanation tonometry (SphygmoCor) Brandt et al. JACC 212 in press
36 Central systolic BP (mmhg) Central PP (mmhg) Effect of RD on central blood pressure Resistant Hypertension; on average 4.8 antihypert. drugs: 11 pts. bilateral RD vs.1 pts. control Central systolic blood pressure Central Pulse Pressure p=.773 p<.1 p<.1 p=.14 p<.1 p<.1 p< p=.753 p<.1 p<.1 p=.24 p<.1 p<.1 p< Baseline 1 Month 3 Months 6 Months Baseline 1 Month 3 Months 6 Months RD, n=11 Control, n=1 Brandt et al. JACC 212 in press
37 Augmentation pressure (mmhg) Augmentation (%) Effect of RD on Augmentation Pressure Resistant Hypertension; on average 4.8 antihypert. drugs: 11 pts. bilateral RD vs.1 pts. control Augmentation Pressure Augmentation Index p<.1 p=.1 p=.3 p=.287 p=.3 p<.1 p< p<.1 p<.1 p=.56 p=.41 p=.47 p=.24 p= Baseline 1 Month 3 Months 6 Months Baseline 1 Month 3 Months 6 Months RD, n=11 Control, n=1 Brandt et al. JACC 212 in press
38 PWV reduction (m/s) Effect of RD on Arterial Stiffness Resistant Hypertension; on average 4.8 antihypert. drugs: 11 pts. bilateral RD vs.1 pts. control Pulse wave velocity Total RD group PWV cf > 9.6 m/s PWV cf > reference -1-2 p= p=.2 p=.1 p=.1 p<.1 p< Month 3 Months 6 Months p=.2 p=.2 p=.4 Brandt et al. JACC 212 in press
39 Relevance of sympathetic overactivity - Beta-blockade is an established treatment in heart failure and hypertension - Renal denervation (RD) or Baroreflex activation significantly reduce peripheral BP and LV-Hypertrophy - RD has the potential to improve diastolic and systolic function - RD has benefical effects on glucose metabolism - RD improves central hemodynamics (seems to be distinct vs. Beta-blockers) - Mortality studies are warrented Therapeutic Implications
40 Relevance of sympathetic overactivity in hypertension and heart failure Therapeutic Implications Uta C. Hoppe, MD, FESC Dep. of Internal Medicine II Paracelsus University Salzburg Austria
41 Renale Denervierung Hypertonus und andere Indikationen Uta C. Hoppe Dep. of Internal Medicine II Paracelsus University Salzburg Austria
Central Pressures and Prehypertension
Central Pressures and Prehypertension Charalambos Vlachopoulos Associate Professor of Cardiology 1 st Cardiology Dept Athens Medical School Central Pressures and Prehypertension Charalambos Vlachopoulos
More informationWhat We've Learned from Simplicity HTN-1,2, and Registries
ANGIOPLASTY SUMMIT-TCTAP 2012 Seoul, Korea, April 24-27, 2012 What We've Learned from Simplicity HTN-1,2, and Registries Horst Sievert, Ann-Kathrin Ziegler, Benjamin Kaltenbach, Ilona Hofmann, Undine Pittl
More informationnoradrenaline spillover and systemic blood pressure in patients with resistant hypertension
Effects of renal sympathetic denervation on noradrenaline spillover and systemic blood pressure in patients with resistant hypertension Markus Schlaich Neurovascular Hypertension & Kidney Disease Laboratory
More informationCATHETER-BASED RENAL DENERVATION INCREASES INSULIN SENSITIVITY AND IMPROVES GLUCOSE METABOLISM IN PATIENTS WITH RESISTANT HYPERTENSION
CATHETER-BASED RENAL DENERVATION INCREASES INSULIN SENSITIVITY AND IMPROVES GLUCOSE METABOLISM IN PATIENTS WITH RESISTANT HYPERTENSION F. Mahfoud, Ch. Ukena, B. Cremers, I. Kindermann, M. Kindermann, P.
More informationHow clinically important are the results of the large trials in hypertension?
How clinically important are the results of the large trials in hypertension? Stéphane LAURENT, MD, PhD, FESC Pharmacology Department and PARCC / INSERM U970 Hôpital Européen Georges Pompidou, Université
More informationAllopurinol reduces left ventricular hypertrophy and endothelial dysfunction in patients with chronic kidney disease
Allopurinol reduces left ventricular hypertrophy and endothelial dysfunction in patients with chronic kidney disease Michelle P Kao, Donald S Ang, Steve Gandy, Chim C Lang, Allan D Struthers Division of
More informationReal World Experience with Renal Denervation Therapy
JCR 2013 Real World Experience with Renal Denervation Therapy Seung-Hyuk Choi Division of Cardiology Samsung Medical Center Seoul, Korea Hypertension A Major Public Health Burden Astonishing prevalence
More informationEvidence of Baroreflex Activation Therapy s Mechanism of Action
Evidence of Baroreflex Activation Therapy s Mechanism of Action Edoardo Gronda, MD, FESC Heart Failure Research Center IRCCS MultiMedica Cardiovascular Department Sesto S. Giovanni (Milano) Italy Agenda
More informationEffects of Renin-Angiotensin System blockade on arterial stiffness and function. Gérard M. LONDON Manhès Hospital Paris, France
Effects of Renin-Angiotensin System blockade on arterial stiffness and function Gérard M. LONDON Manhès Hospital Paris, France Determinants of vascular overload (afterload) on the heart Peripheral Resistance
More informationWhen should you treat blood pressure in the young?
ESC Stockholm - Dilemmas in Cardiovascular Disease Prevention in the Young: 30 th August 2010 When should you treat blood pressure in the young? Bryan Williams MD FRCP FAHA FESC Professor of Medicine Department
More informationArterial stiffness and central BP as goals for antihypertensive therapy in pre- and elderly. Piotr Jankowski
Arterial stiffness and central BP as goals for antihypertensive therapy in pre- and elderly Piotr Jankowski I Department of Cardiology and Hypertension CM UJ, Kraków, Poland piotrjankowski@interia.pl Vienna,
More informationThe Global SYMPLICITY Registry: Safety and Effectiveness of Renal Artery Denervation In Real World Patients With Uncontrolled Hypertension
The Global SYMPLICITY Registry: Safety and Effectiveness of Renal Artery Denervation In Real World Patients With Uncontrolled Hypertension Michael Böhm, MD on behalf of the GSR Investigators March 30,
More informationCatheter Based Denervation for Heart Failure
Catheter Based Denervation for Heart Failure David E. Kandzari, MD, FACC, FSCAI Chief Scientific Officer Director, Interventional Cardiology Piedmont Heart Institute Atlanta, Georgia david.kandzari@piedmont.org
More informationCatheter-Based Renal Denervation Reduces Total Body and Renal Noradrenaline Spillover and Blood Pressure in Resistant Hypertension
Catheter-Based Renal Denervation Reduces Total Body and Renal Noradrenaline Spillover and Blood Pressure in Resistant Hypertension Murray Esler, Markus Schlaich, Paul Sobotka, Rob Whitbourn, Jerzy Sadowski,
More informationOLOMOUC I Study M. Táborský, M. Lazárová, J. Václavík, D. Richter ESC 2012, Munich,
The effect of renal denervation in patients with advanced heart failure: OLOMOUC I Study M. Táborský, M. Lazárová, J. Václavík, D. Richter ESC 2012, Munich, 27.08.2012 Disclosures MT: honoraria Bayer,
More informationUpdate on renal denervation: Latest data
LINC 2018 Update on renal denervation: Latest data Felix Mahfoud Saarland University Hospital, Germany Potential Conflicts of Interest I have the following potential conflicts of interest to report: Research
More informationRenal Artery Denervation New Concepts in Hypertension Treatment
Renal Artery Denervation New Concepts in Hypertension Treatment Istanbul Course of Interventional Cardiology J. Weil Medizinische Klinik II Kardiologie, Angiologie und internistische Intensivmedizin Universitätsklinikum,
More informationTranscatheter Renal Denervation and Hong Kong Experience
Transcatheter Renal Denervation and Hong Kong Experience Dr. Steven Li Siu-lung FACC, FESC, FRCP, FACP Director, Heart Centre, Union Hospital President, Hong Kong Society of Congenital and Structural Heart
More informationCatheter-Based Renal Sympathetic Denervation in the Management of Resistant Hypertension
Catheter-Based Renal Sympathetic Denervation in the Management of Resistant Hypertension Henry Krum, Markus Schlaich, Paul Sobotka, Rob Whitbourn, Jerzy Sadowski, Krzysztof Bartus, Boguslaw Kapelak, Horst
More informationDisclosure of Relationships
Disclosure of Relationships Over the past 12 months Dr Ruilope has served as Consultant and Speakers Bureau member of Astra-Zeneca, Bayer, Daiichi-Sankyo, Menarini, Novartis, Otsuka, Pfizer, Relypsa, Servier
More informationShould beta blockers remain first-line drugs for hypertension?
1 de 6 03/11/2008 13:23 Should beta blockers remain first-line drugs for hypertension? Maros Elsik, Cardiologist, Department of Epidemiology and Preventive Medicine, Monash University and The Alfred Hospital,
More informationAldosterone Antagonism in Heart Failure: Now for all Patients?
Aldosterone Antagonism in Heart Failure: Now for all Patients? Inder Anand, MD, FRCP, D Phil (Oxon.) Professor of Medicine, University of Minnesota, Director Heart Failure Program, VA Medical Center 111C
More informationDanno d organo bersaglio e rischio CV. Persiste un ruolo prognostico oltre la patologia d organo?
Danno d organo bersaglio e rischio CV. Persiste un ruolo prognostico oltre la patologia d organo? Prof. Massimo Salvetti Clinica Medica University of Brescia Percieved risk Actual risk Sehestedt et al,
More informationRISE, FALL AND RESURRECTION OF RENAL DENERVATION. Michael A. Weber, MD State University of New York Downstate College of Medicine
RISE, FALL AND RESURRECTION OF RENAL DENERVATION Michael A. Weber, MD State University of New York Downstate College of Medicine Michael Weber, Disclosures Research/Trial Commitments and Consulting: Boston
More informationSpecial Lecture 11/08/2013. Hypertension Dr. HN Mayrovitz
Special Lecture 11/08/2013 Hypertension Dr. HN Mayrovitz Arterial Blood Pressure (ABP) Major Factors Summarized Sympathetic Hormones Arteriole MAP ~ Q x TPR + f (V / C) SV x HR Renal SBP Hypertension =
More informationRenal Sympathetic Denervation Reduces Left Ventricular Hypertrophy and Improves Cardiac Function in Patients With Resistant Hypertension
Renal Sympathetic Denervation Reduces Left Ventricular Hypertrophy and Improves Cardiac Function in Patients With Resistant Hypertension Mathias C. Brandt, Felix Mahfoud, Sara Reda, Stephan H. Schirmer,
More informationJared Moore, MD, FACP
Hypertension 101 Jared Moore, MD, FACP Assistant Program Director, Internal Medicine Residency Clinical Assistant Professor of Internal Medicine Division of General Medicine The Ohio State University Wexner
More informationCauses of death in Diabetes
Rates of CV events in Diabetes patients Respiratory4.2 Cancer 7.6 Diabetes 1.3 CV disease 17.3 Causes of death in Diabetes 250 200 150 100 50 0 per 10,000 person-years 97 151 243 Framingham 5 X increase
More informationRenal Sympathetic Denervation for Treatment of Resistant Hypertension: 18-Month Results from the Symplicity HTN-2 Randomized Controlled Trial
Renal Sympathetic Denervation for Treatment of Resistant Hypertension: 18-Month Results from the Symplicity HTN-2 Randomized Controlled Trial Prof Murray Esler Baker IDI Heart and Diabetes Institute, Melbourne
More informationTherapeutic Targets and Interventions
Therapeutic Targets and Interventions Ali Valika, MD, FACC Advanced Heart Failure and Pulmonary Hypertension Advocate Medical Group Midwest Heart Foundation Disclosures: 1. Novartis: Speaker Honorarium
More informationUpdate in Hypertension
Update in Hypertension Eliseo J. PérezP rez-stable MD Professor of Medicine DGIM, Department of Medicine UCSF 20 May 2008 Declaration of full disclosure: No conflict of interest (I have never been funded
More informationBaroreflex Activation Therapy: Integrated Autonomic Neuromodulation for Heart Failure and Hypertension
Baroreflex Activation Therapy: Integrated Autonomic Neuromodulation for Heart Failure and Hypertension Robert S. Kieval, VMD, PhD Founder & Chief Technology Officer, CVRx, Inc. Financial Disclosure I,
More informationCIC-P Nancy. Disclosures
Pr Patrick Rossignol Inserm 1433 Clinical Investigation Center Hypertension and Heart Failure Unit Association Lorraine pour le Traitement de l Insuffisance Rénale (ALTIR) CHRU, Lorraine University Nancy,
More informationHTA ET DIALYSE DR ALAIN GUERIN
HTA ET DIALYSE DR ALAIN GUERIN Cardiovascular Disease Mortality General Population vs ESRD Dialysis Patients 100 Annual CVD Mortality (%) 10 1 0.1 0.01 0.001 25-34 35-44 45-54 55-64 66-74 75-84 >85 Age
More informationRenal Denervation. Henry Krum MBBS PhD FRACP. Centre of Cardiovascular Research & Monash University/Alfred Hospital;
Renal Denervation Henry Krum MBBS PhD FRACP Centre of Cardiovascular Research & Education in Therapeutics, Monash University/Alfred Hospital; Alfred Heart Centre, The Alfred Hospital, Melbourne Australia
More informationLCZ696 A First-in-Class Angiotensin Receptor Neprilysin Inhibitor
The Angiotensin Receptor Neprilysin Inhibitor LCZ696 in Heart Failure with Preserved Ejection Fraction The Prospective comparison of ARNI with ARB on Management Of heart failure with preserved ejection
More informationSpecial Lecture 10/28/2012
Special Lecture 10/28/2012 HYPERTENSION Dr. HN Mayrovitz Special Lecture 10/28/2012 Arterial Blood Pressure (ABP) - Definitions ABP Review Indirect Oscillographic Method Resistance (R), Compliance (C)
More informationCatheter-Based Renal Denervation (RDN)
Hypertension lecture 3: Catheter-Based Renal Denervation (RDN) Adapted from slides prepared by Dr IOEBRAHIM, UNITAS HOSPITAL and others Hypertension Epidemiology 30% Untreated 35% Treated & Controlled
More informationMeasurement of Arterial Stiffness: Why should I measure both PWA and PWV?
Measurement of Arterial Stiffness: Why should I measure both PWA and PWV? Central blood pressure and measures of arterial stiffness have been shown to be powerful predictors of major cardiovascular events,
More informationRadiofrequency Energy Provides Safe & Durable Blood Pressure Reduction: Complete 3 Year Results from Symplicity HTN-1
Radiofrequency Energy Provides Safe & Durable Blood Pressure Reduction: Complete 3 Year Results from Symplicity HTN-1 Henry Krum MBBS PhD FRACP FESC for the Symplicity I Investigators CCRE Therapeutics,
More informationDevices and Long-Term Outcomes of Renal Denervation for Hypertension
18th ANGIOPLASTY SUMMIT-TCTAP 2013 Seoul, Korea, April 23-26, 2013 Devices and Long-Term Outcomes of Renal Denervation for Hypertension Horst Sievert, Ilona Hofmann, Laura Vaskelyte, Stefan Bertog, Simon
More informationVALUE OF ACEI IN THE MANAGEMENT OF HYPERTENSION
VALUE OF ACEI IN THE MANAGEMENT OF HYPERTENSION Dr Catherine BESEME Paris 6 th December 2005 6 th International Congress of Bangladesh Society of Medicine Hypertension is a risk factor at the source, with
More informationThe Hearth Rate modulators. How to optimise treatment
The Hearth Rate modulators How to optimise treatment Munich, ESC Congress 2012 Prof. Luigi Tavazzi GVM Care&Research E.S. Health Science Foundation Cotignola, IT Disclosure Cooperation with: Servier, Medtronic,
More informationMANAGEMENT OF HYPERTENSION: TREATMENT THRESHOLDS AND MEDICATION SELECTION
Management of Hypertension: Treatment Thresholds and Medication Selection Robert B. Baron, MD MS Professor and Associate Dean Declaration of full disclosure: No conflict of interest Presentation Goals
More informationHypertension and diabetic nephropathy
Hypertension and diabetic nephropathy Elisabeth R. Mathiesen Professor, Chief Physician, Dr sci Dep. Of Endocrinology Rigshospitalet, University of Copenhagen Denmark Hypertension Brain Eye Heart Kidney
More informationCardiovascular Diseases in CKD
1 Cardiovascular Diseases in CKD Hung-Chun Chen, MD, PhD. Kaohsiung Medical University Taiwan Society of Nephrology 1 2 High Prevalence of CVD in CKD & ESRD Foley RN et al, AJKD 1998; 32(suppl 3):S112-9
More informationRenal denervation: Current evidence and remaining uncertainties
Renal denervation: Current evidence and remaining uncertainties Michel Azizi Georges Pompidou European Hospital Hypertension Unit ESH excellence Center Paris Descartes University Clinical Investigation
More informationHypertension Update Clinical Controversies Regarding Age and Race
Hypertension Update Clinical Controversies Regarding Age and Race Allison Helmer, PharmD, BCACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 22, 2017 DISCLOSURE/CONFLICT
More informationOLOMOUC I Registry. The effect of renal denervation in patients with advanced heart failure:
The effect of renal denervation in patients with advanced heart failure: OLOMOUC I Registry M. Táborský, M. Lazárová, J. Václavík, D. Richter, D. Vindiš, M. Kamasová, A. Louis, J. Jarkovský * I.IKK FNOL,
More informationSlide notes: References:
1 2 3 Cut-off values for the definition of hypertension are systolic blood pressure (SBP) 135 and/or diastolic blood pressure (DBP) 85 mmhg for home blood pressure monitoring (HBPM) and daytime ambulatory
More informationRenal Denervation. by Walead Latif, DO, MBA, CPE Assistant Clinical Professor Rutgers Medical School
Renal Denervation by Walead Latif, DO, MBA, CPE Assistant Clinical Professor Rutgers Medical School Disclosure Information ACOI Annual Meeting I have the following financial relationships to disclose:
More informationΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ. Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH
ΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH Hypertension Co-Morbidities HTN Commonly Clusters with Other Risk
More informationTHE HEART AND HYPERTENSION. Philippe Gosse Hypertension Unit University Hospital Bordeaux
THE HEART AND HYPERTENSION Philippe Gosse Hypertension Unit University Hospital Bordeaux INCREASED LVM Cardiomyocytes hypertrophy is a response to pressure overload This response is influenced by many
More informationIs there a mechanism of interaction between hypertension and dyslipidaemia?
Is there a mechanism of interaction between hypertension and dyslipidaemia? Neil R Poulter International Centre for Circulatory Health NHLI, Imperial College London Daegu, Korea April 2005 Observational
More informationAssociation between arterial stiffness and cardiovascular risk factors in a pediatric population
+ Association between arterial stiffness and cardiovascular risk factors in a pediatric population Maria Perticone Department of Experimental and Clinical Medicine University Magna Graecia of Catanzaro
More informationClinical application of Arterial stiffness. pulse wave analysis pulse wave velocity
Clinical application of Arterial stiffness pulse wave analysis pulse wave velocity Arterial system 1. Large arteries: elastic arteries Aorta, carotid, iliac, Buffering reserve: store blood during systole
More informationADVANCES IN MANAGEMENT OF HYPERTENSION
Advances in Management of Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Prevalence 29%; Blacks 33.5%
More informationUpdate on Current Trends in Hypertension Management
Friday General Session Update on Current Trends in Hypertension Management Shawna Nesbitt, MD Associate Dean, Minority Student Affairs Associate Professor, Department of Internal Medicine Office of Student
More informationManaging anti-hypertensive treatment with SphygmoCor XCEL
Managing anti-hypertensive treatment with SphygmoCor XCEL Measurement of Central aortic BP may provide valuable information on antihypertensive drug action that is not apparent with assessment of Brachial
More informationACE inhibitors: still the gold standard?
ACE inhibitors: still the gold standard? Session: Twenty-five years after CONSENSUS What have we learnt about the RAAS in heart failure? Lars Køber, MD, D.Sci Department of Cardiology Rigshospitalet University
More informationINTERNATIONAL REGISTRY FOR AMBULATORY BLOOD PRESSURE AND ARTERIAL STIFFNESS TELEMONITORING
INTERNATIONAL REGISTRY FOR AMBULATORY BLOOD PRESSURE AND ARTERIAL STIFFNESS TELEMONITORING VASOTENS Registry Vascular health ASsessment Of The hypertensive patients Project Coordinator: Dr. Stefano Omboni
More informationIdentification of patients with heart failure and PREserved systolic Function : an Epidemiologic Regional study
Identification of patients with heart failure and PREserved systolic Function : an Epidemiologic Regional study Dr. Antonio Magaña M.D. (on behalf I-PREFER investigators group) Stockholm, Sweden, August
More informationACE inhibitors vs ARBs Myths and Facts
ACE inhibitors vs ARBs Myths and Facts Prof. Dr. med. Frank Ruschitzka, FRCP (Edinburgh) Director Heart Failure/Transplantation Clinic University Clinic Zurich Switzerland Conflict of interest: Bayer,
More informationHypertension: What s new since JNC 7. Harold M. Szerlip, MD, FACP, FCCP, FASN, FNKF
Hypertension: What s new since JNC 7 Harold M. Szerlip, MD, FACP, FCCP, FASN, FNKF Disclosures Spectral Diagnostics Site investigator Eli Lilly Site investigator ACP IM ITE writing committee NBME Step
More informationHow to assess the hemodynamic importance of a renal artery stenosis. Felix Mahfoud, MD Saarland University Hospital Homburg/Saar, Germany
How to assess the hemodynamic importance of a renal artery stenosis Felix Mahfoud, MD Saarland University Hospital Homburg/Saar, Germany How to assess renal artery stenosis severity 1. Non-invasive assessments
More informationOutcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension
Outcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension Prof. Massimo Volpe, MD, FAHA, FESC, Chair of Cardiology, Department of Clinical and Molecular Medicine
More informationCARDIOVASCULAR RISK FACTORS & TARGET ORGAN DAMAGE IN GREEK HYPERTENSIVES
CARDIOVASCULAR RISK FACTORS & TARGET ORGAN DAMAGE IN GREEK HYPERTENSIVES C. Liakos, 1 G. Vyssoulis, 1 E. Karpanou, 2 S-M. Kyvelou, 1 V. Tzamou, 1 A. Michaelides, 1 A. Triantafyllou, 1 P. Spanos, 1 C. Stefanadis
More informationThe role of physical activity in the prevention and management of hypertension and obesity
The 1 st World Congress on Controversies in Obesity, Diabetes and Hypertension (CODHy) Berlin, October 26-29 2005 The role of physical activity in the prevention and management of hypertension and obesity
More informationHypertension Update 2009
Hypertension Update 2009 New Drugs, New Goals, New Approaches, New Lessons from Clinical Trials Timothy C Fagan, MD, FACP Professor Emeritus University of Arizona New Drugs Direct Renin Inhibitors Endothelin
More informationDepartments of Cardiology and Vascular Surgery Michaelidion Cardiac Center University of Ioannina, Greece
Departments of Cardiology and Vascular Surgery Michaelidion Cardiac Center University of Ioannina, Greece ARGYRIS Vassilis, PEROULIS Michalis, MATSAGKAS Miltiadis, BECHLIOULIS Aris, MICHALIS Lampros, NAKA
More informationWhen blood pressure is measured conventionally over. Hypertension
Hypertension Differential Impact of Blood Pressure Lowering Drugs on Central Aortic Pressure and Clinical Outcomes Principal Results of the Conduit Artery Function Evaluation (CAFE) Study The CAFE Investigators,
More informationBlood Pressure Response Under Chronic Antihypertensive Drug Therapy
Journal of the American College of Cardiology Vol. 53, No. 5, 29 29 by the American College of Cardiology Foundation ISSN 735-197/9/$36. Published by Elsevier Inc. doi:1.116/j.jacc.28.9.46 Hypertension
More informationRole of Sympathetic Nervous System in Hypertension
Role of Sympathetic Nervous System in Hypertension BP = CO x PVR SV HR DEFENSE REACTION Suppressed vagal activity Increased sympathetic activity to heart, veins, kidneys, splachnic region, skin Skeletal
More informationhypertension Head of prevention and control of CVD disease office Ministry of heath
hypertension t. Samavat MD,Cadiologist,MPH Head of prevention and control of CVD disease office Ministry of heath RECOMMENDATIONS FOR HYPERTENSION DIAGNOSIS, ASSESSMENT, AND TREATMENT Definition of hypertension
More informationDefinition of Congestive Heart Failure
Heart Failure Definition of Congestive Heart Failure A clinical syndrome of signs & symptoms resulting from the heart s inability to supply adequate tissue perfusion. CHF Epidemiology Affects 4.7 million
More informationEffects of heart rate reduction with ivabradine on left ventricular remodeling and function:
Systolic Heart failure treatment with the If inhibitor ivabradine Trial Effects of heart rate reduction with ivabradine on left ventricular remodeling and function: results of the SHIFT echocardiography
More informationCombination of renin-angiotensinaldosterone. how to choose?
Combination of renin-angiotensinaldosterone system inhibitors how to choose? Karl Swedberg Professor of Medicine Sahlgrenska Academy University of Gothenburg karl.swedberg@gu.se Disclosures Research grants
More informationHypertension in Geriatrics. Dr. Allen Liu Consultant Nephrologist 10 September 2016
Hypertension in Geriatrics Dr. Allen Liu Consultant Nephrologist 10 September 2016 Annual mortality (%) Cardiovascular Mortality Rates are Higher among Dialysis Patients 100 10 1 0.1 0.01 0.001 25-34
More informationThe Road to Renin System Optimization: Renin Inhibitor
The Road to Renin System Optimization: Renin Inhibitor A New Perspective on the Renin-Angiotensin System (RAS) Yong-Jin Kim, MD Seoul National University Hospital Human and Economic Costs of Hypertension
More informationCoronary artery disease (CAD) risk factors
Background Coronary artery disease (CAD) risk factors CAD Risk factors Hypertension Insulin resistance /diabetes Dyslipidemia Smoking /Obesity Male gender/ Old age Atherosclerosis Arterial stiffness precedes
More informationHypertensive heart disease and failure
Hypertensive heart disease and failure Prof. Dr. Alan Fraser Cardiff University The heart in hypertension Pathophysiology of LV adaptation Regional development of hypertrophy Stress testing - inducible
More informationInfluence of RAAS inhibition on outflow tract obstruction in hypertrophic cardiomyopathy
ORIGINAL ARTICLE 5 RAAS inhibitors should be avoided if possible in patients with obstructive HCM Influence of RAAS inhibition on outflow tract obstruction in hypertrophic cardiomyopathy Katrin Witzel,
More informationEffects of heart rate reduction with ivabradine on left ventricular remodeling and function:
Systolic Heart failure treatment with the If inhibitor ivabradine Trial Effects of heart rate reduction with ivabradine on left ventricular remodeling and function: results of the SHIFT echocardiography
More informationThiazide or Thiazide Like? Choosing Wisely Academic Detailing Conference Digby Pines October 12-14
Thiazide or Thiazide Like? Choosing Wisely Academic Detailing Conference Digby Pines October 12-14 Disclosures Pam McLean-Veysey, Team Leader Drug Evaluation Unit DEU funded by the Drug Evaluation Alliance
More informationClinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8. Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital
Clinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8 Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital Objectives Review the Eighth Joint National Committee (JNC
More informationBy Prof. Khaled El-Rabat
What is The Optimum? By Prof. Khaled El-Rabat Professor of Cardiology - Benha Faculty of Medicine HT. Introduction Despite major worldwide efforts over recent decades directed at diagnosing and treating
More informationEffects of Kidney Disease on Cardiovascular Morbidity and Mortality
Effects of Kidney Disease on Cardiovascular Morbidity and Mortality Joachim H. Ix, MD, MAS Assistant Professor in Residence Division of Nephrology University of California San Diego, and Veterans Affairs
More informationReview of Cardiac Imaging Modalities in the Renal Patient. George Youssef
Review of Cardiac Imaging Modalities in the Renal Patient George Youssef ECHO Left ventricular hypertrophy (LVH) assessment Diastolic dysfunction Stress ECHO Cardiac CT angiography Echocardiography - positives
More informationAntihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
More informationHeart Failure in Women: Dr Goh Ping Ping Cardiologist Asian Heart & Vascular Centre
Heart Failure in Women: More than EF? Dr Goh Ping Ping Cardiologist Asian Heart & Vascular Centre Overview Review pathophysiology as it relates to diagnosis and management Rational approach to workup:
More informationADVANCES IN MANAGEMENT OF HYPERTENSION
Prevalence 29%; Blacks 33.5% About 72.5% treated; 53.5% uncontrolled (>140/90) Risk for poor control: Latinos, Blacks, age 18-44 and 80,
More informationDiastolic Function. Rick Nishimura Leighton Professor of CV Diseases Mayo Clinic No Disclosures
Diastolic Function Rick Nishimura Leighton Professor of CV Diseases Mayo Clinic No Disclosures Heart = Pump Heart Failure Systolic Dysfunction Diastolic Dysfunction Diastole is a complex sequence of multiple
More informationMechanisms of heart failure with normal EF Arterial stiffness and ventricular-arterial coupling. What is the pathophysiology at presentation?
Mechanisms of heart failure with normal EF Arterial stiffness and ventricular-arterial coupling What is the pathophysiology at presentation? Ventricular-arterial coupling elastance Central arterial pressure
More informationIndividual Study Table Referring to Part of Dossier: Volume: Page:
Synopsis Abbott Laboratories Name of Study Drug: Paricalcitol Capsules (ABT-358) (Zemplar ) Name of Active Ingredient: Paricalcitol Individual Study Table Referring to Part of Dossier: Volume: Page: (For
More informationBlood Pressure Goal in Elderly Hypertensive Patients with Diabetes Mellitus: A Subanalysis of the CASE-J Trial
Blood Pressure Goal in Elderly Hypertensive Patients with Diabetes Mellitus: A Subanalysis of the CASE-J Trial Kenji Ueshima 1, Shinji Yasuno 1, Sachiko Tanaka 1, Akira Fujimoto 1, Toshio Ogihara 2, Takao
More informationJNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults
JNC 8 2014 Evidence-Based Guidelines for the Management of High Blood Pressure in Adults Table of Contents Why Do We Treat Hypertension? Blood Pressure Treatment Goals Initial Therapy Strength of Recommendation
More informationManagement of Hypertension
Clinical Practice Guidelines Management of Hypertension Definition and classification of blood pressure levels (mmhg) Category Systolic Diastolic Normal
More informationWith an unrestricted educational grant from. The Interventional Treatment of Resistant Hypertension
With an unrestricted educational grant from The Interventional Treatment of Resistant Hypertension Felix Mahfoud Interventional Cardiology University Hospital Homburg/Saar Germany Dr. Mahfoud graduated
More informationRest and Exercise Echocardiography in Hypertrophic Cardiomyopathy: Determinants of Exercise Peak Gradient and Predictors of Outcome
Rest and Exercise Echocardiography in Hypertrophic Cardiomyopathy: Determinants of Exercise Peak Gradient and Predictors of Outcome G. Deswarte, AS. Polge, N. Lamblin, A. Millaire, M. Richardson, C. Bauters,
More informationCedars Sinai Diabetes. Michael A. Weber
Cedars Sinai Diabetes Michael A. Weber Speaker Disclosures I disclose that I am a Consultant for: Ablative Solutions, Boston Scientific, Boehringer Ingelheim, Eli Lilly, Forest, Medtronics, Novartis, ReCor
More information